Geode Capital Management’s Aptevo Therapeutics APVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$56.9K Buy
+13,337
New +$91.2K ﹤0.01% 4282
2025
Q2
Sell
-29
Closed -$12.2K 4449
2025
Q1
$12.2K Buy
+29
New +$36.7K ﹤0.01% 4422
2024
Q4
Sell
-3
Closed -$7.85K 4475
2024
Q3
$7.85K Buy
3
+2
+200% +$9.21K ﹤0.01% 4495
2024
Q2
$5.93K Buy
+1
New +$14.9K ﹤0.01% 4569
2024
Q1
Hold
0
-$7.82K 4610
2023
Q4
Hold
0
4607
2023
Q3
Hold
0
4581
2023
Q2
Hold
0
4408
2023
Q1
Hold
0
4316
2022
Q4
Hold
0
4321
2022
Q3
Hold
0
4327
2022
Q2
Hold
0
4301
2022
Q1
Hold
0
4168
2021
Q4
Hold
0
4280
2021
Q3
Hold
0
3930
2021
Q2
Hold
0
3676
2021
Q1
Hold
0
3514
2020
Q4
Hold
0
3362
2020
Q3
Hold
0
3946
2020
Q2
Hold
0
3879
2020
Q1
Hold
0
3964
2019
Q4
Hold
0
3980
2019
Q3
Hold
0
3981
2019
Q2
Hold
0
3901
2019
Q1
Hold
0
3891
2018
Q4
Hold
0
3767
2018
Q3
Hold
0
3409
2018
Q2
Hold
0
3401
2018
Q1
Hold
0
3551
2017
Q4
Hold
0
3436
2017
Q3
Hold
0
3643
2017
Q2
Hold
0
3686
2017
Q1
Hold
0
3559
2016
Q4
Hold
0
3500
2016
Q3
Hold
0
3503

Other funds holding APVO

Geode Capital Management's APVO Position: Q1 2026 in Review

Geode Capital Management opened a new position in Aptevo Therapeutics (APVO) in Q1 2026: 13,337 shares worth $56.9K. The stake represents ﹤0.01% of the portfolio and ranks #4282 among its holdings. This is a return to the name: Geode Capital Management previously reported a position in APVO as recently as Q1 2025.

Geode Capital Management first reported a position in APVO in Q2 2024 and has held it in 4 quarters since. 9 funds tracked by Wall St. Rank hold APVO as of Q1 2026.

  • Geode Capital Management held 13,337 shares of Aptevo Therapeutics worth $56.9K as of Q1 2026.
  • Aptevo Therapeutics was a new Geode Capital Management position in Q1 2026.
  • Aptevo Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #4282 holding.
  • Geode Capital Management first reported a position in Aptevo Therapeutics in Q2 2024 and has held it in 4 quarters since.
  • 9 funds tracked by Wall St. Rank held Aptevo Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.